Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | General Counsel and Secretary | October 06, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 94,784 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 1,990 · Balance 96,774 Row 2 · 2026-10-06 · Sale · Disposed 1,990 · Balance 94,784 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.62 · Expires 2027-05-31 | Direct | 81,242 |
Reported balance
After 2026-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-06 · Exercise / conversion · Disposed 1,990 · Balance 81,242 F3: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 8, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,990 | $0.00 Strike: $13.62 | $0.00 |
DisclosureSEC source: 0001193125-26-418101 · ownership.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,242 Underlying: Common Shares · 1,990 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,990 | $60.04 | $119,481.19 |
DisclosureSEC source: 0001193125-26-418101 · ownership.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,784 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 1,990 | $13.62 | $27,103.80 |
DisclosureSEC source: 0001193125-26-418101 · ownership.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,400 | $0.00 Strike: $13.62 | $0.00 |
DisclosureSEC source: 0001193125-26-401237 · ownership.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,232 Underlying: Common Shares · 10,400 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 10,400 | $60.24 | $626,459.60 |
DisclosureSEC source: 0001193125-26-401237 · ownership.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,784 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 10,400 | $13.62 | $141,648.00 |
DisclosureSEC source: 0001193125-26-401237 · ownership.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 476 shares acquired under the CRISPR Therapeutics AG 2026 Employee Stock Purchase Plan. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 21:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-253929 · ownership.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Shares · 17,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: This restricted stock unit award was granted on May 29, 2026 with respect to 17,000 Common Shares, with 100% of the shares vesting on November 29, 2028. F2 · derivative.expiration_date: This restricted stock unit award was granted on May 29, 2026 with respect to 17,000 Common Shares, with 100% of the shares vesting on November 29, 2028. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 21:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,182 | $46.78 | $148,853.96 |
DisclosureSEC source: 0001193125-26-122274 · ownership.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,308 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 21:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-122274 · ownership.xml · derivative · entry 5 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F6 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. F6 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 21:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-122274 · ownership.xml · derivative · entry 4 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F5 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2026 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030. F5 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2026 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 21:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 38,499 | $0.00 Strike: $46.24 | $0.00 |
DisclosureSEC source: 0001193125-26-122274 · ownership.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,499 Underlying: Common Shares · 38,499 shares Expires 2036-03-20 F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F4 · derivative.exercise_date: This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 21:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-122274 · ownership.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,450 | $48.26 | $166,497.00 |
DisclosureSEC source: 0001193125-26-111281 · ownership.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,240 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 6,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-111281 · ownership.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,625 Underlying: Common Shares · 6,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F4 · derivative.exercise_date: This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. F4 · derivative.expiration_date: This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 6,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-111281 · ownership.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 11, 2026 Filed Mar 12, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,800 | $52.80 | $147,840.00 |
DisclosureSEC source: 0001193125-26-104481 · ownership.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,815 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-104481 · ownership.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Shares · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F4 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. F4 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-104481 · ownership.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,112 | $52.58 | $111,048.96 |
DisclosureSEC source: 0001193125-26-061710 · ownership.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,115 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 3,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-061710 · ownership.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. F3 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-061710 · ownership.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| October 14, 2025 Filed Oct 15, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,076 | $66.60 | $71,661.60 |
DisclosureSEC source: 0001193125-25-240437 · ownership.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,402 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 2,114 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-240437 · ownership.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,113 Underlying: Common Shares · 2,114 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F4 · derivative.exercise_date: This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026. F4 · derivative.expiration_date: This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026. Read SEC document |
| October 13, 2025 Filed Oct 15, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 2,114 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-240437 · ownership.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · balance_after: Includes 635 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 21:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $67.74 | $0.00 |
DisclosureSEC source: 0001193125-25-230506 · ownership.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Shares · 16,500 shares Expires 2035-10-03 F1 · derivative.exercise_date: This option was granted on October 3, 2025 with respect to 16,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 3, 2025. Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,185 | $41.23 | $131,317.55 |
DisclosureSEC source: 0000950170-25-043972 · ownership.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,729 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-043972 · ownership.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Shares · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-043972 · ownership.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-041467 · ownership.xml · derivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Shares · 27,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 36,666 | $0.00 Strike: $42.12 | $0.00 |
DisclosureSEC source: 0000950170-25-041467 · ownership.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,666 Underlying: Common Shares · 36,666 shares Expires 2035-03-14 F1 · derivative.exercise_date: This option was granted on March 14, 2025 with respect to 36,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 14, 2025. Read SEC document |
| March 12, 2025 Filed Mar 12, 2025 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,116 | $43.32 | $48,345.12 |
DisclosureSEC source: 0000950170-25-038215 · ownership.xml · nonDerivative · entry 4 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,664 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-038215 · ownership.xml · derivative · entry 6 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F4 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. F4 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-038215 · ownership.xml · nonDerivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,850 | $42.42 | $120,897.00 |
DisclosureSEC source: 0000950170-25-038215 · ownership.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,530 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-038215 · ownership.xml · derivative · entry 5 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Shares · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 23:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-038215 · ownership.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| February 19, 2025 Filed Feb 19, 2025 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,947 | $52.80 | $102,801.60 |
DisclosureSEC source: 0000950170-25-023386 · ownership.xml · nonDerivative · entry 4 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,880 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 3,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023386 · ownership.xml · derivative · entry 6 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,825 Underlying: Common Shares · 3,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F4 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. F4 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023386 · ownership.xml · nonDerivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 9,595 | $53.85 | $516,690.75 |
DisclosureSEC source: 0000950170-25-023386 · ownership.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,002 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 16, 2025 Filed Feb 19, 2025 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023386 · ownership.xml · derivative · entry 5 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on August 16, 2022 with respect to 20,000 Common Shares, with 100% of the shares vesting on February 16, 2025. F3 · derivative.expiration_date: This restricted stock unit award was granted on August 16, 2022 with respect to 20,000 Common Shares, with 100% of the shares vesting on February 16, 2025. Read SEC document |
| February 16, 2025 Filed Feb 19, 2025 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023386 · ownership.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-115696 · ownership.xml · derivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on October 16, 2024 with respect to 30,000 Common Shares, with 100% of the shares vesting on October 16, 2027. F3 · derivative.expiration_date: This restricted stock unit award was granted on October 16, 2024 with respect to 30,000 Common Shares, with 100% of the shares vesting on October 16, 2027. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 18,333 | $0.00 Strike: $49.00 | $0.00 |
DisclosureSEC source: 0000950170-24-115696 · ownership.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,333 Underlying: Common Shares · 18,333 shares Expires 2034-10-16 F1 · derivative.exercise_date: This option was granted on October 16, 2024 with respect to 18,333 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 16, 2024. Read SEC document |
| October 14, 2024 Filed Oct 15, 2024 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,089 | $46.28 | $50,398.92 |
DisclosureSEC source: 0000950170-24-114787 · ownership.xml · nonDerivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,597 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| October 13, 2024 Filed Oct 15, 2024 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 2,113 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114787 · ownership.xml · derivative · entry 3 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,227 Underlying: Common Shares · 2,113 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F4 · derivative.exercise_date: This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026. F4 · derivative.expiration_date: This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026. Read SEC document |
| October 13, 2024 Filed Oct 15, 2024 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 2,113 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114787 · ownership.xml · nonDerivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · balance_after: Includes 399 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-035517 · ownership.xml · derivative · entry 2 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 33,333 | $0.00 Strike: $72.94 | $0.00 |
DisclosureSEC source: 0000950170-24-035517 · ownership.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Shares · 33,333 shares Expires 2034-03-20 F1 · derivative.exercise_date: This option was granted on March 20, 2024 with respect to 33,333 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2024. Read SEC document |
| March 12, 2024 Filed Mar 12, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,146 | $74.44 | $85,308.24 |
DisclosureSEC source: 0000950170-24-030190 · ownership.xml · nonDerivative · entry 4 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,174 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.